Package Leaflet: Information for the User
Anastrozole Aurovitas 1 mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
This medication contains a substance called anastrozol and belongs to a group of medications known as “aromatase inhibitors”. This medication is used to treat breast cancer in women who are in menopause.
This medication acts by reducing the amount of hormones called estrogens that are produced by your body, by blocking a natural bodily substance (an enzyme) called “aromatase”.
Do not take Anastrozol Aurovitas
Do not take this medication if you are in any of the situations described above. If you are unsure, consult your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take this medication.
If you are unsure if any of this affects you, consult your doctor or pharmacist before taking this medication.
Inform hospital staff that you are taking this medication if you are admitted to the hospital.
Other medications and Anastrozol Aurovitas
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.This includes medications you purchase without a prescription and herbal remedies.This is because anastrozol may affect the activity of other medications, and some medications may have an effect on anastrozol.
Do not take anastrozol if you are already being treated with any of the following medications:
If you are in any of these situations, seek advice from your doctor or pharmacist.
Inform your doctor or pharmacist if you are taking the following:
Pregnancy and breastfeeding
Do not take this medication if you are pregnant or breastfeeding. Stop taking this medication if you become pregnant and consult your doctor.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
It is unlikely thatthis medicationwill affect your ability to drive or use any tool or machine. However, occasionally some patients may feel weakness or drowsiness while takingthis medication. If this happens, seek advice from your doctor or pharmacist.
Anastrozol Aurovitas contains lactose
This medication containslactose, which is a type of sugar. If your doctor has told you that you have alactose intolerance, consult with them before taking this medication.
Anastrozol Aurovitas contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Continue taking this medication for the time your doctor or pharmacist tells you to. This is a long-term treatment and you may need to take it for several years.Continue taking this medication for the time your doctor or pharmacist tells you to. This is a long-term treatment and you may need to take it for several years.
Use in children and adolescents
This medication should not be administered to children and adolescents.
If you take more Anastrozol Aurovitas than you should
If you take more anastrozol than you should, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Anastrozol Aurovitas
If you forget to take a dose, take the next dose normally. Do not take a double dose (two doses at the same time) to make up for the missed doses.
If you interrupt treatment with Anastrozol Aurovitas
Do not stop taking the tablets unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Anastrozol Aurovitas and seek urgent medical treatment if you experience any of the following severe but rare side effects.
Very common side effects: can affect more than 1 in 10 people
Common side effects:can affect up to 1 in 10 people
Rare side effects can affect up to 1 in 100 people
Rare side effectscan affect up to 1 in 1,000 people
Effects on your bones
This medicinereduces the levels of hormones called estrogens present in your body. This can reduce the mineral content of your bones. These may be less strong and make fractures more likely. Your doctor will monitor these risks according to the treatment guidelines for bone health in postmenopausal women. You should speak with your doctor about the risks and treatment options.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy.If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Anastrozol Aurovitas Composition
Core:monohydrate lactose, sodium glycolate starch type A (from potato), povidone (K30), and magnesium stearate.
Coating: hypromellose 2910 (6mPas), titanium dioxide (E171), and macrogol.
Product appearance and packaging content
Film-coated tablet.
Anastrozole is a film-coated, biconvex, white tablet, marked with “A1” on one face and smooth on the other. The tablet size is approximately 6.1 mm.
This medication is available in PVC/Aluminum blisters.
Packaging size: 10, 28, 30, 50, 56, 60, 84, 90, 98, and 100 film-coated tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder and manufacturer
Marketing authorization holder
Eugia Pharma (Malta) Limited
Vault 14, Level 2, Valletta Waterfront
Floriana, FRN 1914
Malta
Manufacturer
APL Swift Services (Malta) Ltd
HF26, Hal Far Industrial Estate,
Hal Far, BBG 3000,
Birzebbugia, Malta.
O
Generis Farmacêutica S.A.
Rua Joao De Deus, nº 19
Venda Nova, 2700-487,
Amadora, Portugal.
O
Arrow Generiques S.A.S.
26 Avenue Tony Garnier
69007, Lyon, France.
For more information about this medication, please contact the local representative of the marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
This medication is authorized in the European Economic Area member states with the following names:
PortugalAnastrozol Generis
FranceANASTROZOLE ARROW LAB 1 mg, comprimé pelliculé
GermanyAnastroPUREN 1 mg Filmtabletten
ItalyAnastrozolo Aurobindo Italia
PolandAnastrozole Eugia
SpainAnastrozol Aurovitas 1 mg comprimidos recubiertos con película EFG
Last review date of this prospectus:April 2021
For detailed information about this medication, please visit the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.